echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Dongyang Sunshine GLP-1/FGF21 dual agonist HEC88473 injection was approved for clinical use

    Dongyang Sunshine GLP-1/FGF21 dual agonist HEC88473 injection was approved for clinical use

    • Last Update: 2021-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, the official website of CDE shows that the application for clinical trials of the new drug HEC88473 injection developed by Dongyang Sunshine has been approved by the State Food and Drug Administration by default, and it plans to carry out clinical research on type 2 diabetes and weight loss.


    HEC88473 injection is the first class 1 new drug submitted by Dongyang Pharmaceutical in 2021; insulin degludec injection is a new and ultra-long-acting insulin analogue, with global sales exceeding US$1.


    GLP-1R (glucagon-like peptide-1 receptor) agonists are a type of incretin peptides that can enhance glucose-stimulated insulin secretion and reduce food intake.


    Fibroblast growth factor-21 (FGF21) belongs to the FGF family, which is mainly synthesized by the liver and enters the circulation in the form of endocrine.


    Reference source: Mi Nei.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.